API CAS 1454846-35-5 Lorlatinib Powder Lorlatinib Intermediate Lorlatinib
China API CAS 1454846-35-5 Lorlatinib Powder Lorlatinib Intermediate Lorlatinib, Find details about China Lorlatinib, Lorlatinib Powder from API CAS 1454846-35-5 Lorlatinib Powder Lorlatinib Intermediate Lorlatinib
Basic Info.
Model NO.
Condavo-Lorlatinib
Name
Lorlatinib
Product Name
Lorlatinib Powder
Appearance
White Powder
Color
White Color
Test Method
HPLC UV
Storage
Cool Dry Place
Shelf Life
2 Years
Assay
99%
Grade
Medicine Grade
COA
Available
CAS
1454846-35-5
Mf
C21h19fn6o2
MW
406.421
Density
1.42
Boiling Point
675.0c
Trademark
Condavo
Transport Package
1kg/ Aluminium Bag or 25kg/Drum; as Required
Specification
99%
Origin
Shaanxi
Model NO.
Condavo-Lorlatinib
Name
Lorlatinib
Product Name
Lorlatinib Powder
Appearance
White Powder
Color
White Color
Test Method
HPLC UV
Storage
Cool Dry Place
Shelf Life
2 Years
Assay
99%
Grade
Medicine Grade
COA
Available
CAS
1454846-35-5
Mf
C21h19fn6o2
MW
406.421
Density
1.42
Boiling Point
675.0c
Trademark
Condavo
Transport Package
1kg/ Aluminium Bag or 25kg/Drum; as Required
Specification
99%
Origin
Shaanxi
Product Desciption
API CAS 1454846-35-5 Lorlatinib powder Lorlatinib Intermediate Lorlatinib
| Product Name | Lorlatinib |
| CAS | 1454846-35-5 |
| Appearance | White crystalline powder |
| MF | C21H19FN6O2 |
| MW | 406.421 |
| Purity | 99% |
| Shelf Life | 2 Years |
Lorlatinib (PF-06463922) is a new drug under development for the sub-group of advanced non-small cell lung cancerwho are ALK or ROS1 positive and have already undergone gene treatment with drugs thatspecifically targetthis type of cancer.Lorlatinib is currently being evaluated in phase II clinical trials as an oral dose at 100 mg daily. If marketed it will becomean additional targeted treatment for this sub-group of ALKor ROS1 positive patients.
Laroratinib (PF-06463922) is an ALK inhibitor modified from Crizotinib, which entered clinical trials in 2014 for the treatment of Chemicalbook lung cancer.It is mainly targeted at patients with non-small cell lung cancer who are resistant to the first-generation ALK inhibitors crizotinib and resistant to the second-generation ALK inhibitors Ceritinib and Alectinib.
You Might Also Like
Plastic Paving Concrete Mold DIY Walkway Stones Mould Landsc......
Baroque Freshwater Pearl Necklace fashion Jewelry Jewellery ......
China Professional Made Super Big Size Ductile Iron Flange P......
Supermarket Storage Container Plastic Folding Stackable Coll......
Plastic Disposable Hitachi Beckman Sample Cup
Bulk Pen Drive Wood USB Flash Drive
Debo 5 Years Warranty HPL Toilet Cubicle Board
Luxury Hotel 1500 Supreme Collection Bed Sheet Set
Sodium Hyaluronic Acid Gel Injection for Lip, Face, Nose, Br......
Fenugreek Seed Extract 4-Hydroxyisoleucine for Improve Insul......
Rechargeable Battery 25ah 3.2V LiFePO4 Battery Cell
Radial Truck Tyre 10.00r20 11.00r20 12.00r20, TBR